1. Home
  2. HUBB vs NTRA Comparison

HUBB vs NTRA Comparison

Compare HUBB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hubbell Inc

HUBB

Hubbell Inc

HOLD

Current Price

$481.82

Market Cap

23.5B

Sector

Technology

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$196.59

Market Cap

28.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBB
NTRA
Founded
1888
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.5B
28.0B
IPO Year
2004
2015

Fundamental Metrics

Financial Performance
Metric
HUBB
NTRA
Price
$481.82
$196.59
Analyst Decision
Buy
Strong Buy
Analyst Count
8
14
Target Price
$520.38
$259.07
AVG Volume (30 Days)
532.6K
1.1M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.13%
N/A
EPS Growth
15.10
0.65
EPS
16.54
N/A
Revenue
$5,844,600,000.00
$210,939,000.00
Revenue This Year
$10.31
$18.16
Revenue Next Year
$5.43
$20.00
P/E Ratio
$30.48
N/A
Revenue Growth
3.84
N/A
52 Week Low
$299.43
$125.38
52 Week High
$533.80
$256.36

Technical Indicators

Market Signals
Indicator
HUBB
NTRA
Relative Strength Index (RSI) 46.16 44.22
Support Level $472.14 $194.03
Resistance Level $505.77 $204.34
Average True Range (ATR) 16.75 6.54
MACD 1.65 0.81
Stochastic Oscillator 37.47 51.11

Price Performance

Historical Comparison
HUBB
NTRA

About HUBB Hubbell Inc

Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, in electrical substations, and in commercial and industrial buildings. The company's primary operations are in the United States, where around 90% of revenue is derived.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: